AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANVS
  4. [Form 4] Annovis Bio, Inc. Insider Trading Activity

[Form 4] Annovis Bio, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Annovis Bio (ANVS) Vice President of Finance Andrew Walsh reported a new acquisition of company shares on Form 4. The transaction details include:

  • Acquired 500 shares of Common Stock
  • Purchase price: $2.90 per share
  • Transaction date: June 16, 2025
  • Total transaction value: $1,450
  • Ownership type: Direct

Following this transaction, Walsh holds 500 shares directly. The purchase represents an initial position for the executive, as no prior holdings were reported. The transaction was reported within the required two-business-day filing window, with the Form 4 being filed on June 28, 2025. No derivative securities were involved in this transaction.

Il Vicepresidente della Finanza di Annovis Bio (ANVS), Andrew Walsh, ha segnalato un nuovo acquisto di azioni della societ脿 tramite il Modulo 4. I dettagli della transazione sono i seguenti:

  • Acquisto di 500 azioni di azioni ordinarie
  • Prezzo di acquisto: 2,90 $ per azione
  • Data della transazione: 16 giugno 2025
  • Valore totale della transazione: 1.450 $
  • Tipo di propriet脿: Diretta

Dopo questa operazione, Walsh detiene direttamente 500 azioni. L'acquisto rappresenta una posizione iniziale per il dirigente, poich茅 non erano state segnalate partecipazioni precedenti. La transazione 猫 stata comunicata entro la finestra obbligatoria di due giorni lavorativi, con il Modulo 4 depositato il 28 giugno 2025. Non sono stati coinvolti strumenti derivati in questa operazione.

El Vicepresidente de Finanzas de Annovis Bio (ANVS), Andrew Walsh, inform贸 sobre una nueva adquisici贸n de acciones de la empresa mediante el Formulario 4. Los detalles de la transacci贸n incluyen:

  • Adquisici贸n de 500 acciones de acciones comunes
  • Precio de compra: 2,90 $ por acci贸n
  • Fecha de la transacci贸n: 16 de junio de 2025
  • Valor total de la transacci贸n: 1.450 $
  • Tipo de propiedad: Directa

Tras esta transacci贸n, Walsh posee 500 acciones de forma directa. La compra representa una posici贸n inicial para el ejecutivo, ya que no se reportaron participaciones previas. La transacci贸n fue reportada dentro del plazo requerido de dos d铆as h谩biles, present谩ndose el Formulario 4 el 28 de junio de 2025. No se involucraron valores derivados en esta operaci贸n.

Annovis Bio(ANVS)鞚� 鞛 攵�靷灔 Andrew Walsh臧� Form 4毳� 韱淀暣 須岇偓 欤检嫕 鞁犼窚 旆摑鞚� 氤搓碃頄堨姷雼堧嫟. 瓯半灅 靹鸽秬 靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤� 500欤� 旆摑
  • 毵れ瀰 臧�瓴�: 欤茧嫻 2.90雼煬
  • 瓯半灅 鞚检瀽: 2025雲� 6鞗� 16鞚�
  • 齑� 瓯半灅 旮堨暋: 1,450雼煬
  • 靻岇湢 順曧儨: 歆侅爲 氤挫湢

鞚措矆 瓯半灅 頉� Walsh電� 500欤茧ゼ 歆侅爲 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞚措矆 毵れ瀰鞚� 鞛勳洂鞚� 齑堦赴 歆�攵� 旆摑鞚� 鞚橂頃橂┌, 鞚挫爠鞐愲姅 氤挫湢 欤检嫕鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 瓯半灅電� 鞖旉惮霅橂姅 2鞓侅梾鞚� 鞚措偞鞐� 鞁犼碃霅橃棃鞙茧┌, Form 4電� 2025雲� 6鞗� 28鞚检棎 鞝滌稖霅橃棃鞀惦媹雼�. 鞚� 瓯半灅鞐愲姅 韺岇儩 歃濌秾鞚� 韽暔霅橃 鞎婌晿鞀惦媹雼�.

Le vice-pr茅sident des finances d'Annovis Bio (ANVS), Andrew Walsh, a d茅clar茅 une nouvelle acquisition d'actions de la soci茅t茅 via le Formulaire 4. Les d茅tails de la transaction sont les suivants :

  • Acquisition de 500 actions ordinaires
  • Prix d'achat : 2,90 $ par action
  • Date de la transaction : 16 juin 2025
  • Valeur totale de la transaction : 1 450 $
  • Type de propri茅t茅 : Directe

Suite 脿 cette transaction, Walsh d茅tient directement 500 actions. Cet achat repr茅sente une position initiale pour le dirigeant, aucune d茅tention ant茅rieure n'ayant 茅t茅 d茅clar茅e. La transaction a 茅t茅 d茅clar茅e dans le d茅lai requis de deux jours ouvrables, le Formulaire 4 ayant 茅t茅 d茅pos茅 le 28 juin 2025. Aucun titre d茅riv茅 n'a 茅t茅 impliqu茅 dans cette op茅ration.

Andrew Walsh, Vizepr盲sident Finanzen von Annovis Bio (ANVS), meldete einen neuen Aktienerwerb des Unternehmens 眉ber Formular 4. Die Transaktionsdetails lauten wie folgt:

  • Erwerb von 500 Stammaktien
  • Kaufpreis: 2,90 $ pro Aktie
  • Transaktionsdatum: 16. Juni 2025
  • Gesamtwert der Transaktion: 1.450 $
  • Eigentumsart: Direkt

Nach dieser Transaktion h盲lt Walsh direkt 500 Aktien. Der Kauf stellt eine Anfangsposition f眉r den Gesch盲ftsf眉hrer dar, da zuvor keine Beteiligungen gemeldet wurden. Die Transaktion wurde innerhalb des vorgeschriebenen Zwei-Gesch盲ftstage-Meldezeitraums gemeldet, wobei das Formular 4 am 28. Juni 2025 eingereicht wurde. Es waren keine derivativen Wertpapiere an dieser Transaktion beteiligt.

Positive
  • None.
Negative
  • None.

Il Vicepresidente della Finanza di Annovis Bio (ANVS), Andrew Walsh, ha segnalato un nuovo acquisto di azioni della societ脿 tramite il Modulo 4. I dettagli della transazione sono i seguenti:

  • Acquisto di 500 azioni di azioni ordinarie
  • Prezzo di acquisto: 2,90 $ per azione
  • Data della transazione: 16 giugno 2025
  • Valore totale della transazione: 1.450 $
  • Tipo di propriet脿: Diretta

Dopo questa operazione, Walsh detiene direttamente 500 azioni. L'acquisto rappresenta una posizione iniziale per il dirigente, poich茅 non erano state segnalate partecipazioni precedenti. La transazione 猫 stata comunicata entro la finestra obbligatoria di due giorni lavorativi, con il Modulo 4 depositato il 28 giugno 2025. Non sono stati coinvolti strumenti derivati in questa operazione.

El Vicepresidente de Finanzas de Annovis Bio (ANVS), Andrew Walsh, inform贸 sobre una nueva adquisici贸n de acciones de la empresa mediante el Formulario 4. Los detalles de la transacci贸n incluyen:

  • Adquisici贸n de 500 acciones de acciones comunes
  • Precio de compra: 2,90 $ por acci贸n
  • Fecha de la transacci贸n: 16 de junio de 2025
  • Valor total de la transacci贸n: 1.450 $
  • Tipo de propiedad: Directa

Tras esta transacci贸n, Walsh posee 500 acciones de forma directa. La compra representa una posici贸n inicial para el ejecutivo, ya que no se reportaron participaciones previas. La transacci贸n fue reportada dentro del plazo requerido de dos d铆as h谩biles, present谩ndose el Formulario 4 el 28 de junio de 2025. No se involucraron valores derivados en esta operaci贸n.

Annovis Bio(ANVS)鞚� 鞛 攵�靷灔 Andrew Walsh臧� Form 4毳� 韱淀暣 須岇偓 欤检嫕 鞁犼窚 旆摑鞚� 氤搓碃頄堨姷雼堧嫟. 瓯半灅 靹鸽秬 靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤� 500欤� 旆摑
  • 毵れ瀰 臧�瓴�: 欤茧嫻 2.90雼煬
  • 瓯半灅 鞚检瀽: 2025雲� 6鞗� 16鞚�
  • 齑� 瓯半灅 旮堨暋: 1,450雼煬
  • 靻岇湢 順曧儨: 歆侅爲 氤挫湢

鞚措矆 瓯半灅 頉� Walsh電� 500欤茧ゼ 歆侅爲 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞚措矆 毵れ瀰鞚� 鞛勳洂鞚� 齑堦赴 歆�攵� 旆摑鞚� 鞚橂頃橂┌, 鞚挫爠鞐愲姅 氤挫湢 欤检嫕鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 瓯半灅電� 鞖旉惮霅橂姅 2鞓侅梾鞚� 鞚措偞鞐� 鞁犼碃霅橃棃鞙茧┌, Form 4電� 2025雲� 6鞗� 28鞚检棎 鞝滌稖霅橃棃鞀惦媹雼�. 鞚� 瓯半灅鞐愲姅 韺岇儩 歃濌秾鞚� 韽暔霅橃 鞎婌晿鞀惦媹雼�.

Le vice-pr茅sident des finances d'Annovis Bio (ANVS), Andrew Walsh, a d茅clar茅 une nouvelle acquisition d'actions de la soci茅t茅 via le Formulaire 4. Les d茅tails de la transaction sont les suivants :

  • Acquisition de 500 actions ordinaires
  • Prix d'achat : 2,90 $ par action
  • Date de la transaction : 16 juin 2025
  • Valeur totale de la transaction : 1 450 $
  • Type de propri茅t茅 : Directe

Suite 脿 cette transaction, Walsh d茅tient directement 500 actions. Cet achat repr茅sente une position initiale pour le dirigeant, aucune d茅tention ant茅rieure n'ayant 茅t茅 d茅clar茅e. La transaction a 茅t茅 d茅clar茅e dans le d茅lai requis de deux jours ouvrables, le Formulaire 4 ayant 茅t茅 d茅pos茅 le 28 juin 2025. Aucun titre d茅riv茅 n'a 茅t茅 impliqu茅 dans cette op茅ration.

Andrew Walsh, Vizepr盲sident Finanzen von Annovis Bio (ANVS), meldete einen neuen Aktienerwerb des Unternehmens 眉ber Formular 4. Die Transaktionsdetails lauten wie folgt:

  • Erwerb von 500 Stammaktien
  • Kaufpreis: 2,90 $ pro Aktie
  • Transaktionsdatum: 16. Juni 2025
  • Gesamtwert der Transaktion: 1.450 $
  • Eigentumsart: Direkt

Nach dieser Transaktion h盲lt Walsh direkt 500 Aktien. Der Kauf stellt eine Anfangsposition f眉r den Gesch盲ftsf眉hrer dar, da zuvor keine Beteiligungen gemeldet wurden. Die Transaktion wurde innerhalb des vorgeschriebenen Zwei-Gesch盲ftstage-Meldezeitraums gemeldet, wobei das Formular 4 am 28. Juni 2025 eingereicht wurde. Es waren keine derivativen Wertpapiere an dieser Transaktion beteiligt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Walsh Andrew
(Last) (First) (Middle)
C/O ANNOVIS BIO, INC.
101 LINDENWOOD DR, SUITE 225
(Street)
MALVERN PA 19355
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Vice President, Finance
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 A 500 A $2.9 500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Andrew Walsh 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many shares of ANVS stock did Andrew Walsh acquire on June 16, 2025?

According to the Form 4 filing, Andrew Walsh acquired 500 shares of ANVS common stock on June 16, 2025 at a price of $2.90 per share.

What position does Andrew Walsh hold at ANVS (Annovis Bio)?

Andrew Walsh serves as Vice President, Finance at Annovis Bio, Inc. (ANVS) as disclosed in the Form 4 filing.

What was the total value of Andrew Walsh's ANVS stock purchase on June 16, 2025?

The total value of Andrew Walsh's stock purchase was $1,450, calculated from 500 shares acquired at $2.90 per share.

How many shares of ANVS does Andrew Walsh own following this transaction?

Following this transaction, Andrew Walsh directly owns 500 shares of ANVS common stock, held in Direct (D) ownership form.

Did Andrew Walsh acquire any derivative securities of ANVS in this Form 4 filing?

No, the Form 4 filing shows no acquisition or disposition of derivative securities (such as options or warrants) by Andrew Walsh. The transaction only involved common stock.
Stock ANVS logo
Annovis Bio Inc

NYSE:ANVS

ANVS Rankings

#7872 Ranked by Market Cap
N/A Ranked by Dividends

ANVS Latest News

Aug 7, 2025
Annovis Completes Full Patent Transfer to Crystal Buntanetap
Jun 26, 2025
Annovis to Attend the AAIC 2025 with Four Poster Presentations
Jun 19, 2025
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
Jun 5, 2025
Annovis to Host Webinar and Live Q&A on June 24, 2025
May 13, 2025
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

ANVS Latest SEC Filings

Jun 23, 2025
[8-K] Annovis Bio, Inc. Reports Material Event
Jun 20, 2025
[8-K] Annovis Bio, Inc. Reports Material Event

ANVS Stock Data

53.00M
16.62M
14.69%
16.03%
12.63%
Biotechnology
Pharmaceutical Preparations
United States
MALVERN